Search Results - "DEJONGH, Joost"

A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy by DeJongh, Joost, Ahsman, Maurice, Snelder, Nelleke

“…Intermittent androgen deprivation therapy with gonadotropin-releasing-hormone (GnRH) agonists can prevent or delay disease progression and development of…”
Get full text

Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development by Noort, Martijn, Ruppert, Martijn, DeJongh, Joost, Marostica, Eleonora, Bosch, Rolien, Mešić, Emir, Snelder, Nelleke

“…In pharmacometric modeling, it is often important to know whether the data is sufficiently rich to identify the parameters of a proposed model. While it may be…”
Get full text

Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK‐448, for its anti‐tumor efficacy in a rat xenograft model by Kogame, Akifumi, Ishikawa, Kaori, DeJongh, Joost, Tagawa, Yoshihiko, Matsui, Hisanori, Moriya, Yuu, Kondo, Takahiro, Asahi, Satoru

“…TAK‐448 is the investigational metastin/kisspeptin analog, which is known to have an anti‐tumor effect through suppression of androgen hormones (luteinizing…”
Get full text

Pharmacokinetics of recombinant human antithrombin in delivery and surgery patients with hereditary antithrombin deficiency by DeJongh, Joost, Frieling, Johan, Lowry, Simon, Drenth, Henk-Jan

“…Population pharmacokinetic (PK) analyses were conducted to refine dosing recommendations for recombinant human anti-thrombin therapy in surgery and delivery…”
Get more information

Pharmacokinetics of Clindamycin in Pregnant Women in the Peripartum Period by MULLER, Anouk E, MOUTON, Johan W, OOSTVOGEL, Paul M, JOEP DÖRR, P, VOSKUYL, Rob A, DEJONGH, Joost, STEEGERS, Eric A. P, DANHOF, Meindert

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus by DE WINTER, Willem, DEJONGH, Joost, POST, Teun, PLOEGER, Bart, URQUHART, Richard, MOULES, Ian, ECKLAND, David, DANHOF, Meindert

“…Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder. This paper…”
Get full text

THE PHARMACOKINETICS OF GLYCYRRHIZIC ACID EVALUATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING by Ploeger, Bart, Mensinga, Tjeert, Sips, Adriënne, Seinen, Willem, Meulenbelt, Jan, DeJongh, Joost

“…Glycyrrhizic acid is widely applied as a sweetener in food products and chewing tobacco. In addition, it is of clinical interest for possible treatment of…”
Get full text

Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design by Bender, Gregor, Gosset, James, Florian, Jeff, Tan, Keith, Field, Mark, Marshall, Scott, DeJongh, Joost, Bies, Robert, Danhof, Meindert

“…Purpose Preliminary evidence has suggested a synergistic interaction between pregabalin and sildenafil for the treatment of neuropathic pain. The focus of this…”
Get full text

Pharmacokinetics of Amoxicillin in Maternal, Umbilical Cord, and Neonatal Sera by Muller, Anouk E, Oostvogel, Paul M, DeJongh, Joost, Mouton, Johan W, Steegers, Eric A P, Dörr, P Joep, Danhof, Meindert, Voskuyl, Rob A

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks by MULLER, Anouk E, DEJONGH, Joost, BULT, Ymka, GOESSENS, Wil H. F, MOUTON, Johan W, DANHOF, Meindert, VAN DEN ANKER, John N

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes by Muller, Anouk E., MD, DeJongh, Joost, PhD, Oostvogel, Paul M., MD, PhD, Voskuyl, Rob A., PhD, Dörr, P. Joep, MD, PhD, Danhof, Meindert, PharmD, PhD, Mouton, Johan W., MD, PhD

“…Objective This study was undertaken to study the pharmacokinetics of intravenously administered amoxicillin in pregnant women with preterm premature rupture of…”
Get full text

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling by Ploeger, Bart A., Meulenbelt, Jan, DeJongh, Joost

“…Glycyrrhizic acid is currently of clinical interest for treatment of chronic hepatitis. It is also applied as a sweetener in food products and chewing tobacco…”
Get full text

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar by Stringer, Frances, DeJongh, Joost, Scott, Graham, Danhof, Meindert

“…The pharmacokinetics of sipoglitazar, a peroxisome proliferator activated receptor agonist, are subject to high inter‐individual variability resulting from a…”
Get full text

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes by Stringer, Frances, DeJongh, Joost, Enya, Kazuaki, Koumura, Emiko, Danhof, Meindert, Kaku, Kohei

“…This study applied a pharmacodynamic model-based approach to evaluate the long-term durability and glycemic control of pioglitazone in comparison with other…”
Get more information

Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years by Knibbe, Catherijne A. J., Krekels, Elke H. J., van den Anker, Johannes N., DeJongh, Joost, Santen, Gijs W. E., van Dijk, Monique, Simons, Sinno H. P., van Lingen, Richard A., Jacqz-Aigrain, Evelyne M., Danhof, Meindert, Tibboel, Dick

“…Background and objective A considerable amount of drug use in children is still unlicensed or off-label. In order to derive rational dosing schemes, the…”
Get full text

Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation by Goto, Akihiko, Tagawa, Yoshihiko, Moriya, Yuu, Sato, Sho, Yamamoto, Masami, Wakabayashi, Takeshi, Tsukamoto, Tetsuya, DeJongh, Joost, Steeg, Tamara J., Moriwaki, Toshiya, Asahi, Satoru

“…A recent study suggested that the pharmacokinetics (PK) of highly fat distributed compounds can be affected by acute changes in the volume of adipose tissue…”
Get full text

Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK‐357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation by Goto, Akihiko, Tagawa, Yoshihiko, Moriya, Yuu, Sato, Sho, Furukawa, Yoshiyuki, Wakabayashi, Takeshi, Tsukamoto, Tetsuya, DeJongh, Joost, Steeg, Tamara J., Moriwaki, Toshiya, Asahi, Satoru

“…In a dog toxicokinetic study, an unusual plasma concentration increase of the highly lipophilic compound TAK‐357 was observed 2 weeks after termination of a…”
Get full text

Disease system analysis: basic disease progression models in degenerative disease by Post, Teun M, Freijer, Jan I, DeJongh, Joost, Danhof, Meindert

“…To describe the disease status of degenerative diseases (i.e., type 2 diabetes mellitus, Parkinson's disease) as function of disease process and treatment…”
Get full text

Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children by Krekels, Elke H. J., DeJongh, Joost, van Lingen, Richard A., van der Marel, Caroline D., Choonara, Imti, Lynn, Anne M., Danhof, Meindert, Tibboel, Dick, Knibbe, Catherijne

“…Background and Objective Model validation procedures are crucial when models are to be used to develop new dosing algorithms. In this study, the predictive…”
Get full text

Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar by Stringer, Frances, Ploeger, Bart A., Jongh, Joost De, Scott, Graham, Urquhart, Richard, Karim, Aziz, Danhof, Meindert

“…Sipoglitazar is a peroxisome proliferator–activated receptor α, δ, and γ agonist. During phase I, a wide distribution of clearance between individuals was…”
Get full text